Kevin Sprott

This inventor holds 21 USPTO granted patents and 17 published patent applications, plus 6 CIPO patents and 6 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Syros Pharmaceuticals, Inc., Ironwood Pharmaceuticals, Inc., Millennium Pharmaceuticals Limited. Active years: 2007-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Kevin Sprott. Retrieved from https://idiyas.com/inventor/kevin-sprott

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 21 (Patent Applications = 17)

% Patents Active = 71.4

CIPO Patents = 6 (Patent Applications = 5)

EPO Patents = 6 (Patent Applications = 13)

Average Co-Inventor Count = 9.4

ph-index = 6

Forward Citations = 86(Granted Patents)

Location History:

Boston, MA (US) (2007 - 2011)
Needham, MA (US) (2014 - 2023)

Company Filing History:

11 out of 24

Syros Pharmaceuticals, Inc.

patents

4 out of 44

Ironwood Pharmaceuticals, Inc.

patents

4 out of 854

Millennium Pharmaceuticals Limited

patents

4. 3 out of 1,268

Dana-Farber-Cancer Institute Inc.

patents

where one patent can have more than one assignee

Years Active: 2007-2023

Loading Chart...

Areas of Expertise:

CDK7 Inhibitors

Myc Modulation

Heteroaromatic Compounds

Polycyclic Inhibitors

FAAH Inhibitors

Indole Compounds

CRTH2 Modulators

CCR2 Antagonists

PGD2 Receptor Antagonists

Proliferative Diseases

Inflammatory Diseases

21 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11753418 - Compounds for the modulation of Myc activity (2023-09-12),

2. 11274103 - Compounds for the modulation of MYC activity (2022-03-15),

3. 11124527 - Compounds for the modulation of Myc activity (2021-09-21),

4. 11040957 - Heteroaromatic compounds useful for the treatment of proliferative diseases (2021-06-22),

5. 10906889 - Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7) (2021-02-02),

6. 10865206 - Inhibitors of cyclin-dependent kinase 7 (CDK7) (2020-12-15),

7. 10787444 - Compounds for the modulation of myc activity (2020-09-29),

8. 10519135 - Inhibitors of cyclin-dependent kinase 7 (CDK7) (2019-12-31),

9. 10336760 - Inhibitors of cyclin-dependent kinase 7 (CDK7) (2019-07-02),

10. 10308648 - Inhibitors of cyclin-dependent kinase 7 (CDK7) (2019-06-04),

11. 10106526 - Inhibitors of cyclin-dependent kinase 7 (CDK7) (2018-10-23),

12. 10059690 - Inhibitors of cyclin-dependent kinase 7 (CDK7) (2018-08-28),

13. 10047070 - Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7) (2018-08-14),

14. 9657012 - FAAH inhibitors (2017-05-23),

15. 8884020 - Indole compounds (2014-11-11),

Title: The Innovative Journey of Kevin Sprott

Introduction: Kevin Sprott, a talented inventor based in Needham, MA (US), has made significant contributions to the field of technology through his creative and groundbreaking inventions.

Latest Patents: Kevin Sprott holds several patents in various technological domains, showcasing his versatility and ingenuity in creating novel solutions to complex problems.

Career Highlights: Throughout his illustrious career, Kevin Sprott has been recognized for his innovative spirit and dedication to pushing the boundaries of technology. His inventions have not only improved existing processes but have also opened up new possibilities in the tech industry.

Collaborations: Kevin Sprott has collaborated with leading tech companies and research institutions to further develop and refine his inventions. His ability to work effectively in a team setting has led to successful partnerships and groundbreaking innovations.

Conclusion: Kevin Sprott's passion for innovation and his relentless pursuit of excellence have established him as a prominent figure in the world of technology. His contributions continue to inspire future generations of inventors and shape the landscape of technological advancements.

Profile summary based on public USPTO records.